PIK3CA and breast carcinoma: In addition, promising results demonstrating decreased FDG uptake on PET scan performed 2 weeks on alpelisib, a PI3K inhibitor, in correlation to PFS has been observed in early phase clinical trials for ER-positive breast cancers (51).